David Rosmarin, Ahmed M Soliman, Simran Marwaha, James Piercy, Heidi S Camp, Peter Anderson, Khaled Ezzedine
{"title":"Disease Course, Treatment Patterns and Goals Among Patients with Non-segmental Vitiligo Across Europe and the United States.","authors":"David Rosmarin, Ahmed M Soliman, Simran Marwaha, James Piercy, Heidi S Camp, Peter Anderson, Khaled Ezzedine","doi":"10.1007/s13555-024-01212-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There is currently a lack of research regarding disease course and burden as well as treatment patterns and goals in patients with non-segmental vitiligo (NSV). The aim of this analysis was to evaluate disease course, treatment patterns and goals in patients with NSV.</p><p><strong>Methods: </strong>This analysis used secondary data from the Adelphi Real World Vitiligo Disease Specific Programme<sup>™</sup> 2021, specifically, a survey of physicians and their adult and adolescent patients with NSV. Physicians categorized patients by the extent of NSV at time of survey completion as mild, moderate or severe/very severe. Physician-reported patient information included demographics, current/previously prescribed NSV therapies, treatment satisfaction and the Vitiligo Noticeability Scale (VNS). Patients completed a survey on treatment satisfaction and the VNS. Treatment pattern data were stratified by disease extent and Fitzpatrick skin type.</p><p><strong>Results: </strong>At survey completion, physicians reported that 38, 50 and 12% of patients (N = 1865) had improving, stable and deteriorating/progressing disease, respectively. Most patients (96%) with mild disease at treatment initiation still had mild disease at the time of survey completion. More than half of patients with moderate disease (62%) or severe/very severe disease (57%) at treatment initiation still had moderate or severe/very severe disease at survey completion. Topical calcineurin inhibitors (TCIs) were the most common treatment in 40% of patients followed by phototherapy in 30%. Patients hoped for re-pigmentation (mild 56%, moderate 62%, severe/very severe 66%), reduction (mild 50%, moderate 56%, severe/very severe 49%) or cessation of affected areas with vitiligo (mild 48%, moderate 54%, severe/very severe 43%).</p><p><strong>Conclusion: </strong>The study findings indicate that a significant proportion of patients with NSV are not improving on current treatments, most commonly TCIs and phototherapy. The results highlight the unmet need for novel and effective therapies to substantially improve re-pigmentation, an important treatment goal for patients with NSV.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265022/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-024-01212-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: There is currently a lack of research regarding disease course and burden as well as treatment patterns and goals in patients with non-segmental vitiligo (NSV). The aim of this analysis was to evaluate disease course, treatment patterns and goals in patients with NSV.
Methods: This analysis used secondary data from the Adelphi Real World Vitiligo Disease Specific Programme™ 2021, specifically, a survey of physicians and their adult and adolescent patients with NSV. Physicians categorized patients by the extent of NSV at time of survey completion as mild, moderate or severe/very severe. Physician-reported patient information included demographics, current/previously prescribed NSV therapies, treatment satisfaction and the Vitiligo Noticeability Scale (VNS). Patients completed a survey on treatment satisfaction and the VNS. Treatment pattern data were stratified by disease extent and Fitzpatrick skin type.
Results: At survey completion, physicians reported that 38, 50 and 12% of patients (N = 1865) had improving, stable and deteriorating/progressing disease, respectively. Most patients (96%) with mild disease at treatment initiation still had mild disease at the time of survey completion. More than half of patients with moderate disease (62%) or severe/very severe disease (57%) at treatment initiation still had moderate or severe/very severe disease at survey completion. Topical calcineurin inhibitors (TCIs) were the most common treatment in 40% of patients followed by phototherapy in 30%. Patients hoped for re-pigmentation (mild 56%, moderate 62%, severe/very severe 66%), reduction (mild 50%, moderate 56%, severe/very severe 49%) or cessation of affected areas with vitiligo (mild 48%, moderate 54%, severe/very severe 43%).
Conclusion: The study findings indicate that a significant proportion of patients with NSV are not improving on current treatments, most commonly TCIs and phototherapy. The results highlight the unmet need for novel and effective therapies to substantially improve re-pigmentation, an important treatment goal for patients with NSV.
导言：目前，有关非节段性白癜风（NSV）患者的病程、负担以及治疗模式和目标的研究还很缺乏。本分析旨在评估非节段性白癜风患者的病程、治疗模式和目标：这项分析使用了 2021 年阿德尔菲真实世界白癜风疾病专项计划（Adelphi Real World Vitiligo Disease Specific Programme™ 2021）的二手数据，特别是对医生及其成年和青少年 NSV 患者的调查。在完成调查时，医生根据患者的 NSV 程度将其分为轻度、中度或重度/极重度。医生报告的患者信息包括人口统计学特征、当前/之前开具的 NSV 治疗处方、治疗满意度和白癜风可察觉性量表 (VNS)。患者填写了一份关于治疗满意度和 VNS 的调查表。治疗模式数据按疾病程度和菲茨帕特里克皮肤类型进行分层：调查结束时，医生报告说分别有38%、50%和12%的患者（1865人）病情好转、稳定和恶化/进展。大多数在开始治疗时病情较轻的患者（96%）在完成调查时病情仍然较轻。在开始治疗时病情为中度（62%）或重度/极重度（57%）的患者中，一半以上在调查结束时病情仍为中度或重度/极重度。局部降钙素抑制剂（TCIs）是最常见的治疗方法，占 40% 的患者，其次是光疗，占 30%。患者希望重新获得色素沉着（轻度56%，中度62%，重度/极重度66%）、减轻（轻度50%，中度56%，重度/极重度49%）或停止患处的白癜风（轻度48%，中度54%，重度/极重度43%）：研究结果表明，相当一部分 NSV 患者在接受现有治疗（最常见的是 TCIs 和光疗）后病情未见好转。研究结果凸显了对新型有效疗法的需求尚未得到满足，而新型有效疗法可大幅改善色素再沉着，这是 NSV 患者的一个重要治疗目标。
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
